Kodamaea ohmeri is an emerging invasive fungal pathogen, with limited data from low- and middle-income countries. We describe the epidemiology, clinical characteristics, and outcomes of neonatal K. ohmeri bloodstream infection in two tertiary care hospitals in Bangladesh. We conducted prospective surveillance among neonates admitted to neonatal intensive care units of two tertiary care hospitals between August 2022 and June 2026. Fungal isolates were identified using VITEK 2 and confirmed using VITEK MS. Antifungal susceptibility testing (AFST) was performed on a subset of isolates using two gradient diffusion strip tests. Among 770 enrolled neonates, 12.3% (n = 95) had bloodstream infection caused by K. ohmeri, accounting for 27.1% of all positive fungal isolates. Clinical characteristics were comparable between K. ohmeri and other fungal infections. Among the positive K. ohmeri cases, 57.9% (n = 55) received antifungal therapy. AFST showed relatively higher fluconazole MICs than voriconazole, amphotericin B, and echinocandins. However, mortality was numerically lower among patients who received antifungal therapy than among those who did not, although the association was not statistically significant in either unadjusted (p = 0.09) or adjusted (p = 0.065) analyses. The high burden and associated mortality of K. ohmeri bloodstream infections highlight the importance of strengthening species-level fungal identification and antifungal stewardship in resource-limited NICUs. Continued surveillance and further investigations linking antifungal susceptibility with clinical outcomes are warranted to inform evidence-based management.